Amgen, Inc.  

(Public, NASDAQ:AMGN)   Watch this stock  
Find more results for AMGN
162.24
-1.94 (-1.18%)
After Hours: 162.24 0.00 (0.00%)
Nov 25, 6:37PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 160.70 - 164.41
52 week 108.20 - 165.68
Open 164.06
Vol / Avg. 3.56M/4.83M
Mkt cap 124.53B
P/E 25.53
Div/yield 0.61/1.50
EPS 6.35
Shares 760.67M
Beta 0.51
Inst. own 83%
Jan 26, 2015
Q4 2014 Amgen Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 8, 2014
Amgen Inc Conference Call at American Society of Hematology Annual Meeting - 3:00PM EST - Add to calendar
Nov 19, 2014
Amgen Inc at Jefferies Global Healthcare Conference - London - Webcast
Nov 18, 2014
Amgen Inc Conference Call to Discuss Evolocumab Development Program at AHA - Webcast
Nov 11, 2014
Amgen Inc at Credit Suisse Healthcare Conference
Oct 28, 2014
Amgen Inc 2014 Business Review Meeting - Webcast
Oct 27, 2014
Q3 2014 Amgen Inc Earnings Call - Webcast
Oct 27, 2014
Q3 2014 Amgen Inc Earnings Release
Sep 29, 2014
Amgen Inc Conference Call on Kyprolis at ESMO - Webcast
Sep 10, 2014
Amgen at Morgan Stanley Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 24.73% 27.21%
Operating margin 29.14% 31.41%
EBITD margin - 39.90%
Return on average assets 7.11% 8.44%
Return on average equity 20.08% 24.69%
Employees 20,000 -
CDP Score - 76 B

Address

One Amgen Center Drive
THOUSAND OAKS, CA 91320-1799
United States - Map
+1-805-4471000 (Phone)
+1-805-4471010 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha
About Company - Wikipedia

Description

Amgen Inc. (Amgen) is a global biotechnology company that discovers, develops, manufactures and delivers human therapeutics. It focuses its research and development activities on human therapeutics for in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular and general medicine, which includes neuroscience. The Company�s marketed products include Neulasta, NEUPOGEN, ENBREL, Aranesp, EPOGEN, Sensipar/Mimpara, XGEVA and Prolia. In addition to its marketed products, the Company has various product candidates in mid-to late-stage of development. The Company markets its principal products primarily in the United States in cancer care, inflammation, nephrology and bone disease. As of February 17, 2014, the Company has 16 Phase III programs.

Officers and directors

Robert A. Bradway Chairman of the Board, President, Chief Executive Officer
Age: 51
Bio & Compensation  - Reuters
David W. Meline Chief Financial Officer, Executive Vice President
Age: 56
Bio & Compensation  - Reuters
Madhavan Balachandran Executive Vice President - Operations
Age: 63
Bio & Compensation  - Reuters
Sean E. Harper Executive Vice President - Research and Development
Age: 51
Bio & Compensation  - Reuters
Anthony C. Hooper Executive Vice President - Global Commercial Operations
Age: 59
Bio & Compensation  - Reuters
Brian M. McNamee Executive Vice President - Full Potential Initiatives
Age: 57
Bio & Compensation  - Reuters
Cynthia M. Patton Senior Vice President, Chief Compliance Officer
Age: 52
Bio & Compensation  - Reuters
David J. Scott Senior Vice President, General Counsel, Secretary
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Stuart A. Tross Senior Vice President - Human Resources
Age: 47
Bio & Compensation  - Reuters
Steven K. Galson M.D. Senior Vice President - Global Regulatory Affairs And Safety
Age: 57
Bio & Compensation  - Reuters